
|Videos|December 20, 2022
CheckMate 274: Data Updates in MIBC from GU ASCO, ASCO, and ESMO 2022
Author(s)Terence Friedlander, MD
Terence Friedlander, MD, continues his discussion of the CheckMate 247 trial by highlighting important updates from recent conferences on adjuvant nivolumab therapy in patients with MIBC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5









































